The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients

被引:270
作者
Filipsson, Helena
Monson, John P.
Koltowska-Haggstrom, Maria
Mattsson, Anders
Johannsson, Gudmundur
机构
[1] Gothenburg Univ, Sahlgrenska Acad, Dept Endocrinol, SE-41345 Gothenburg, Sweden
[2] Queen Mary Univ London, St Bartholomews Hosp, London EC1A 7BE, England
[3] Pfizer, Endocrine Care, KIGS,KIMS,ACROSTUDY Med Outcomes, SE-19190 Sollentuna, Sweden
[4] Uppsala Univ, Dept Pharm, Uppsala, Sweden
关键词
D O I
10.1210/jc.2006-0524
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Hypopituitary patients with untreated GH deficiency and patients on inappropriately high doses of glucocorticoid ( GC) share certain clinical features. Objective: The aim of the study was to examine the influence of GC substitution on clinical characteristics in hypopituitary patients before and after GH replacement therapy. Method: A total of 2424 hypopituitary patients within the KIMS ( Pfizer International Metabolic Database) were grouped according to ACTH status. Comparisons were performed between subjects on hydrocortisone (HC) (n = 1186), cortisone acetate (CA) (n = 487), and prednisolone/dexamethasone (n = 52), and ACTH-sufficient patients (AS) (n = 717) before and after 1 yr of GH treatment in terms of body mass index, waist and hip circumference, blood pressure, glucose, glycosylated hemoglobin (HbA1c), serum lipids, IGF-I, and comorbidity. Hydrocortisone equivalent (HCeq) doses were calculated, and measurements were adjusted for sex and age. Results: At baseline, the HC group had increased total cholesterol, triglycerides, waist circumference, and HbA1c, and the prednisolone/ dexamethasone group had increased waist/hip ratio as compared with AS. After HCeq dose adjustment, the HC group retained higher HbA1c than the CA group. GC-treated patients showed a dose-related increase in serum IGF-I, body mass index, triglycerides, low-density lipoprotein cholesterol and total cholesterol levels. Subjects with HCeq doses less than 20 mg/d (n = 328) at baseline did not differ from AS in metabolic endpoints. The 1-yr metabolic response to GH was similar in all GC groups and dose categories. All new cases of diabetes (n = 12), stroke (n = 8), and myocardial infarction (n = 3) during GH treatment occurred in GC-treated subjects. Conclusion: HCeq doses of at least 20 mg/d in adults with hypopituitarism are associated with an unfavorable metabolic profile. CA replacement may have metabolic advantages compared with other GCs.
引用
收藏
页码:3954 / 3961
页数:8
相关论文
共 42 条
[1]   GH replacement in 1034 growth hormone deficient hypopituitary adults:: demographic and clinical characteristics, dosing and safety [J].
Abs, R ;
Bengtsson, BÅ ;
Hernberg-Ståhl, E ;
Monson, JP ;
Tauber, JP ;
Wilton, P ;
Wüster, C .
CLINICAL ENDOCRINOLOGY, 1999, 50 (06) :703-713
[2]   EFFECT OF GLUCOCORTICOID REPLACEMENT THERAPY ON GLUCOSE-TOLERANCE AND INTERMEDIARY METABOLITES IN HYPOPITUITARY ADULTS [J].
ALSHOUMER, KAS ;
BESHYAH, SA ;
NITHTHYANANTHAN, R ;
JOHNSTON, DG .
CLINICAL ENDOCRINOLOGY, 1995, 42 (01) :85-90
[3]   ENDOCRINE AND METABOLIC DISEASES - ADRENAL DISEASES [J].
BESSER, GM ;
JEFFCOATE, WJ .
BRITISH MEDICAL JOURNAL, 1976, 1 (6007) :448-451
[4]  
BOLAND EDWARD W., 1958, CALIFORNIA MED, V88, P417
[6]   IGF-I levels rise and GH responses to GHRH decrease during long-term prednisone treatment in man [J].
Borges, MHS ;
Pinto, ACAR ;
DiNinno, FB ;
Camacho-Hübner, C ;
Grossman, A ;
Kater, CE ;
Lengyel, AMJ .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1999, 22 (01) :12-17
[7]   Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system:: Results from a multicenter study [J].
Brabant, G ;
von zur Mühlen, A ;
Wüster, C ;
Ranke, MB ;
Kratzsch, J ;
Kiess, W ;
Ketelslegers, JM ;
Wilhelmsen, L ;
Hulthén, L ;
Saller, B ;
Mattsson, A ;
Wilde, J ;
Schemer, R ;
Kann, P .
HORMONE RESEARCH, 2003, 60 (02) :53-60
[8]   AMELIORATION OF INSULIN-RESISTANCE IN DIABETES WITH DEHYDROEPIANDROSTERONE [J].
BUFFINGTON, CK ;
POURMOTABBED, G ;
KITABCHI, AE .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1993, 306 (05) :320-324
[9]   METABOLIC EFFECTS OF METACORTANDRALONE AND METACORTANDRACIN [J].
BUNIM, JJ ;
BLACK, RL ;
BOLLET, AJ ;
PECHET, MM .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1955, 61 (02) :358-368
[10]   Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis [J].
Canalis, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (10) :3441-3447